Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adenosine receptor ligands-recent developments part I. Agonists.

C E Muller1

  • 1Pharmaceutical Institute, University of Bonn, Bonn, Germany. christa.mueller@uni-bonn.de

Current Medicinal Chemistry
|October 18, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chemical composition and physical characteristics of faeces in horses with and without free faecal liquid - two case-control studies.

BMC veterinary research·2022
Same author

Hippocampal synaptic dysfunction in the SOD1<sup>G93A</sup> mouse model of Amyotrophic Lateral Sclerosis: Reversal by adenosine A<sub>2A</sub>R blockade.

Neuropharmacology·2020
Same author

Caffeine modulates voluntary alcohol intake in mice depending on the access conditions: Involvement of adenosine receptors and the role of individual differences.

Pharmacology, biochemistry, and behavior·2019
Same author

Anti-inflammatory effect of a novel locally acting A<sub>2A</sub> receptor agonist in a rat model of oxazolone-induced colitis.

Purinergic signalling·2017
Same author

Contribution of platelet P2Y<sub>12</sub> receptors to chronic Complete Freund's adjuvant-induced inflammatory pain.

Journal of thrombosis and haemostasis : JTH·2017
Same author

A2A adenosine receptor deletion is protective in a mouse model of Tauopathy.

Molecular psychiatry·2015
Same journal

Knockdown of circFGFR2 inhibits prostate cancer cell metastasis and proliferation by targeting miR-221-5p/ SMUG1 pathway.....

Current medicinal chemistry·2026
Same journal

LncRNA signature associated with amino acid metabolism: A novel prognostic tool for Clear Cell Renal Cell Carcinoma.

Current medicinal chemistry·2026
Same journal

HRI Kinase Modulation by BTdCPU as a Therapeutic Strategy for Bortezomib Resistance in Prostate Cancer.

Current medicinal chemistry·2026
Same journal

EGFR Dysregulation in Cancer: From Molecular Mechanisms and Key Mutations to Evolving TKI Strategies and Resistance Mitigation.

Current medicinal chemistry·2026
Same journal

DHRS2 as a Novel Thalidomide Target Regulating Mitophagy and Inflammation in Head and Neck Squamous Cell Carcinoma.

Current medicinal chemistry·2026
Same journal

Synthetic AtMP2 from Anabas testudineus: Comprehensive ADMET and In Vivo Toxicity Assessment to Enable Future Therapeutic Development.

Current medicinal chemistry·2026
See all related articles

Recent advancements in adenosine receptor (AR) agonists reveal challenges in achieving subtype selectivity. While potent A(1) and A(3) AR agonists exist, selective A(2A) and A(2B) agonists remain elusive, prompting development of indirect agents.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Drug Discovery

Background:

  • Adenosine receptors (ARs) are crucial drug targets.
  • Four subtypes (A(1), A(2A), A(2B), A(3)) have been identified and cloned.
  • Recombinant ARs are widely used for ligand screening.

Purpose of the Study:

  • To review recent developments in adenosine receptor agonist research.
  • To discuss the challenges and progress in developing selective AR agonists.
  • To explore alternative strategies for AR-targeted therapies.

Main Methods:

  • Review of existing literature on AR agonists.
  • Analysis of data from recombinant AR assays.
  • Reevaluation of compound selectivity across all four AR subtypes.

Related Experiment Videos

Main Results:

  • Potent and selective agonists for A(1) and A(3) ARs have been developed.
  • Many previously considered selective agonists show cross-reactivity, particularly at the A(3) subtype.
  • Truly selective A(2A) and potent/selective A(2B) agonists are currently unavailable.

Conclusions:

  • Achieving subtype-selective AR agonists remains a significant challenge.
  • Non-selectivity, especially for A(3) ARs, is a common issue.
  • Development is shifting towards partial agonists, indirect agonists (e.g., adenosine kinase inhibitors), and allosteric modulators for site- and event-specific actions.